| human | Q5 |
| P7893 | CIÊNCIAVITAE ID | 7111-3383-A926 |
| P2798 | Loop ID | 476379 |
| P496 | ORCID iD | 0000-0003-0176-5585 |
| P3829 | Publons author ID | 2570631 |
| P1053 | ResearcherID | A-6252-2014 |
| P1153 | Scopus author ID | 6602731390 |
| P214 | VIAF ID | 99557943 |
| P69 | educated at | University of Lisbon | Q1122926 |
| P108 | employer | Instituto Universitário Egas Moniz | Q10302689 |
| P734 | family name | Taveira | Q37558939 |
| Taveira | Q37558939 | ||
| Taveira | Q37558939 | ||
| P735 | given name | Nuno | Q19828514 |
| Nuno | Q19828514 | ||
| P106 | occupation | researcher | Q1650915 |
| P5008 | on focus list of Wikimedia project | WikiProject COVID-19 | Q87748614 |
| P21 | sex or gender | male | Q6581097 |
| Q37512840 | A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus |
| Q91779794 | A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies |
| Q37517645 | A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support |
| Q55075340 | A65 Mitochondrial DNA studies of Lisbon immigrants from Portuguese speaking African countries. |
| Q58870939 | Accidental Father-to-Son HIV-1 Transmission During the Seroconversion Period |
| Q41208456 | Amplification of full-length HIV-2 envelope genes. |
| Q42713370 | An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity |
| Q37448301 | Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates |
| Q37247746 | Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance |
| Q40197811 | Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients |
| Q38915512 | Baseline susceptibility of primary HIV-2 to entry inhibitors |
| Q54261664 | Clonal expansion across the seas as seen through CPLP-TB database: A joint effort in cataloguing Mycobacterium tuberculosis genetic diversity in Portuguese-speaking countries |
| Q56971877 | Construction and characterization of CD4-independent infectious recombinant HIV-2 molecular clones |
| Q91152098 | Correction to "Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides" |
| Q55349380 | Correction: Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. |
| Q56971913 | Detection of HIV-1 DNA by polymerase chain reaction incorporation of digoxigenin-11-dUTP and hybridization to immobilized probes |
| Q44707645 | Detection of HIV1 proviral DNA by PCR and hybridization with digoxigenin labelled probes |
| Q33553629 | Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012 |
| Q35983629 | Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors |
| Q41051936 | Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. |
| Q40040133 | Donor-Recipient Identification in Para- and Poly-phyletic Trees Under Alternative HIV-1 Transmission Hypotheses Using Approximate Bayesian Computation. |
| Q40120069 | Early infant diagnosis of HIV-1 infection in Luanda, Angola, using a new DNA PCR assay and dried blood spots |
| Q43770623 | Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression |
| Q56395674 | Epidemic history of hepatitis C virus genotypes and subtypes in Portugal |
| Q35156353 | Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms |
| Q46700373 | Evaluation of the diagnostic performance of the rapid test VIKIA HIV1/2 in a highly complex HIV-1 epidemic |
| Q52580522 | Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. |
| Q48148785 | Evidence for negative selective pressure in HIV-2 evolution in vivo |
| Q33591409 | Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response |
| Q33809419 | Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection |
| Q46638450 | Genetic diversity and drug resistance profiles in HIV type 1- and HIV type 2-infected patients from Cape Verde Islands |
| Q38946645 | Genetic diversity, transmission dynamics and drug resistance of Mycobacterium tuberculosis in Angola |
| Q38775511 | Genetic diversity, transmission dynamics, and drug resistance of Mycobacterium tuberculosis in Luanda, Angola |
| Q91434055 | Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy |
| Q59117458 | Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 |
| Q59137381 | Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 |
| Q59137378 | Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Dise |
| Q59131985 | Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 |
| Q28542528 | HIV-1 diversity, transmission dynamics and primary drug resistance in Angola |
| Q46986567 | HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique |
| Q33966596 | HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients |
| Q43425262 | High genetic diversity of human immunodeficiency virus type 1 in Angola |
| Q30370063 | Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic. |
| Q58542679 | In vitro evaluation of novel reverse transcriptase inhibitors TAF and OBP-601 against multi-drug resistant primary isolates of HIV-2 |
| Q90891599 | Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody |
| Q90754787 | Mapping 123 million neonatal, infant and child deaths between 2000 and 2017 |
| Q59131975 | Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017 |
| Q45729269 | Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia |
| Q92610614 | Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance |
| Q92715401 | Mitochondrial DNA in human identification: a review |
| Q48085410 | Molecular characterization of the env gene from a non-syncytium-inducing HIV-2 isolate (HIV-2ALI) |
| Q30391799 | On the contribution of Angola to the initial spread of HIV-1. |
| Q34039423 | Origin and epidemiological history of HIV-1 CRF14_BG. |
| Q33769693 | Outbreak of acute respiratory infection among infants in Lisbon, Portugal, caused by human adenovirus serotype 3 and a new 7/3 recombinant strain |
| Q56971888 | Perinatally acquired HIV-2 infection diagnosed at 15 and 24 years of age |
| Q45524572 | Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthood |
| Q36525347 | Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. |
| Q47614093 | Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells |
| Q34290973 | Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy |
| Q95627827 | Predicting the evolution and control of COVID-19 pandemic in Portugal. |
| Q35077691 | Predictors of attrition and immunological failure in HIV-1 patients on highly active antiretroviral therapy from different healthcare settings in Mozambique. |
| Q45735643 | Production and characterization of a mouse monoclonal antibody against the Gag p26 protein of human immunodeficiency virus type 2: identification of a new antigenic epitope. |
| Q56971842 | Rapid clinical progression to AIDS and death in a persistently seronegative HIV-1 infected heterosexual young man |
| Q30387160 | Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola |
| Q39213845 | Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism |
| Q56971870 | Seronegative infection and AIDS caused by an A2 subsubtype HIV-1 |
| Q45724156 | Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection |
| Q91186253 | Spiro-Lactams as Novel Antimicrobial Agents |
| Q104741236 | Spiro-β-lactam BSS-730A Displays Potent Activity against HIV and Plasmodium |
| Q28119353 | Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling study |
| Q33274194 | Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics |
| Q43143940 | The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients |
| Q34430673 | Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins |
| Q44310356 | Vertical transmission of HIV-2. |
Search more.